Pharmaceutical shortages open up debate on reshoring of API manufacturing
Panel at CPHI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency
US and European pharmaceutical companies are actively considering ways to diversify their supply chains – including the possible reshoring of drug and ingredients manufacturing – in the light of drug shortages that arose early in the COVID-19 pandemic, according to experts in a recent live panel discussion at the CPHI Festival of Pharma.
The virtual session, sponsored by Aspen Pharma, was focused on how growing globalisation of the active pharmaceutical ingredients (API) market had affected supply chains and whether measures were needed to avoid future bottlenecks.
Martin Van Trieste, President & CEO at Civica Rx said there are always around 250 drug shortages in the US at any one time, most of them older generic drugs such as sterile injectables, and blamed the situation on the economics of generics, describing generic pricing as a race to the bottom to get the lowest possible price.
“Individuals and companies don’t want to make the investments in manufacturing facilities and upgrades and expansions, so they have moved their entire supply chain offshore to places like India and China – this has developed a very long, complex supply chain that’s very fragile and at the end of the day, the patients suffer,” he said.
He added that at the height of the COVID-19 pandemic in the second quarter there were 50 countries that refused to export either personal protective equipment, diagnostic tests, reagents, pharmaceutical precursors, APIs and finished products: “That’s been a wake-up call for many governments around the world that the diversification of the pharmaceutical supply chain, including onshoring, is going to be required.”
Rene Zoetmulder, procurement lead at Aspen API said that pharmaceutical companies operating in Europe were seriously considering reshoring production into the continent as well as looking at different technologies to take a greener approach.
“That is a long-term programme in Europe – they have created a roadmap to do it step by step, and of course it will take a lot of time,” he said, adding that the regulatory limitations of switching and improving the system had been acknowledged.
He said that from Aspen’s perspective, the company had managed to maintain its relationships with its materials suppliers in China by actively keeping a presence in the country and not relying exclusively on agents.
“If you look at the recent COVID situation, where there was an immediate shortage of some materials, we were able to more than double immediately the output of a drug used during ventilation of patients in IC without having any issues with the availability of the materials,” he said. “You need to make sure that you have the chain under control, you go hand in hand, and you are actively managing it – then you won’t have any surprises.”
Luca Zambelli - Board member of the Chemical Pharmaceutical Association and Managing Director of Galentis, said that drug shortages were currently a “hot topic” within Europe.
He gave the example of the Medicines: policy, authorisation and monitoring unit at the European Directorate-General for Health and Food Safety recently communicating that by the end of the year, Europe should provide a document outlining a strategy to prevent medicines shortages.
He said there was a “lack of knowledge in Europe” about the true extent of the continent’s dependence on overseas supply for API manufacturing, quoting a recent report claiming that only 15% of European APIs are dependent on supply from China or India.
“The problem is how do we make these APIs?” he said. “The true story is that 85% of this material [manufactured in Europe] is made from starting materials, or advanced or early stage intermediates from China.”
He said that rather than focusing on reshoring of production, European companies should rather focus on the development of new manufacturing technologies in order to compete effectively with India and China.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance